Join Drs Carol Wysham and Silvio Inzucchi as they discuss how type 2 diabetes management has evolved over the years, and the most promising developments on the horizon.

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.


Continuous Glucose Monitoring in Persons With Type 2 Diabetes Not Using Insulin

Macrovascular Complications of Type 2 Diabetes Mellitus

Rate of Decline in Kidney Function and Known Age-of-Onset or Duration of Type 2 Diabetes

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Tirzepatide Prescribing Information

Glycemic Targets: Standards of Care in Diabetes-2023

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update

2018 ESC/ESH Guidelines for the Management of Arterial Hypertension

The Role of BNP Testing in Heart Failure

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Rationale and Design

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

GLP-1 Receptor Agonists and Kidney Protection

Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Podden och tillhörande omslagsbild på den här sidan tillhör Medscape. Innehållet i podden är skapat av Medscape och inte av, eller tillsammans med, Poddtoppen.